Yesafili, a vascular endothelial growth factor inhibitor, is used to treat several different types of ophthalmology ...

Regeneron aims for FDA approval of extended dosing for EYLEA HD in AMD and DME, with a decision by April 2025. Pre-filled ...

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

With a market cap of $62.4 billion, Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...

Lined up for the FDA in the coming weeks are a cell-based gene therapy for a rare skin disease and two product expansions for ...

Biocon Biologics and Regeneron settled to commercialize aflibercept-jbvf in the US, resolving patent litigation. The agreement allows Biocon to launch Yesafili in the US by the second half of 2026, or ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Additionally, Biocon Biologics secured a settlement agreement in Canada with Bayer and Regeneron Pharma for launch of YESAFILI no later than July 1, 2025.

As Fierce Pharma points out, patent expirations are a routine occurrence in the pharmaceutical world, but 2025 stands out for ...

BRIDGEWATER, NJ, USA and BENGALURU, Karnataka, India I April 15, 2025 I Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and ...

Biocon Biologics has secured market entry for its biosimilar product Yesafili in the US after reaching a settlement agreement with Regeneron. Yesafili, a biosimilar of Eylea (aflibercept), will be ...

Biocon Biologics secures market entry date for Yesafili, an interchangeable biosimilar to Eylea, in US: Our Bureau, Bengaluru Tuesday, April 15, 2025, 11:30 Hrs [IST] Biocon Biolo ...